Literature review and methodological considerations for understanding circulating risk biomarkers following trauma exposure

Sarah D Linnstaedt1,2, Anthony S Zannas1,3,4, Samuel A McLean1,2,5, Karestan C Koenen6, Kerry J Ressler7

1Institute for Trauma Recovery, University of North Carolina, Chapel Hill, NC
2Department of Anesthesiology, University of North Carolina, Chapel Hill, NC
3Departments of Psychiatry and Genetics, University of North Carolina, Chapel Hill, NC
4Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
5Department of Emergency Medicine, University of North Carolina, Chapel Hill, NC
6Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
7Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA

Abstract

Exposure to traumatic events is common. While many individuals recover following trauma exposure, a substantial subset develop adverse posttraumatic neuropsychiatric sequelae (APNS) such as posttraumatic stress, major depression, and regional or widespread chronic musculoskeletal pain. APNS cause substantial burden to the individual and to society, causing functional impairment and physical disability, risk for suicide, lost workdays, and increased health care costs. Contemporary treatment is limited by an inability to identify individuals at high risk of APNS in the immediate aftermath of trauma, and an inability to identify optimal treatments for individual patients. Our purpose is to provide a comprehensive review describing candidate blood-based biomarkers that may help to identify those at high risk of APNS and/or guide individual intervention decision-making. Such blood-based biomarkers include circulating biological factors such as hormones, proteins, immune molecules, neuropeptides, neurotransmitters, mRNA and noncoding RNA expression signatures, while we do not review genetic and epigenetic biomarkers due to other recent reviews of this topic. The current state of the literature on circulating risk biomarkers of APNS is summarized, and key considerations and challenges for their discovery and translation are discussed. We also describe the AURORA study, a specific example of current...
scientific efforts to identify such circulating risk biomarkers and the largest study to date focused on identifying risk and prognostic factors in the aftermath of trauma exposure.

Keywords
Trauma; PTSD; Pain; Depression; Substance Abuse; RNA; microRNA; prediction; resilience

Introduction
Exposure to traumatic events is common\textsuperscript{2, 3}. While many individuals recover following trauma exposure, a substantial subset develop adverse posttraumatic neuropsychiatric sequelae (APNS). APNS, as previously defined\textsuperscript{4}, can include a wide range of neuropsychiatric outcomes; three of the most common APNS are posttraumatic stress (PTS), major depression, and regional or widespread chronic musculoskeletal pain (CMP). These APNS cause tremendous suffering, functional impairment, high health care costs, and are a leading cause of disability among current and former members of the armed forces.\textsuperscript{5–14}

Individuals who develop APNS often present for emergency care or other health care in the immediate/early aftermath of the inciting event, creating the opportunity to initiate secondary preventive interventions to those at high risk. Risk stratification tools are applied to tens of thousands of trauma survivors in Emergency Departments throughout the US every day, including both clinician assessments (e.g., CCR and NEXUS\textsuperscript{17} criteria for cervical fracture risk) and blood-based biomarkers (e.g., lactate\textsuperscript{18–20}, base deficit\textsuperscript{28, 29}). Unfortunately, no risk prediction tools are in common use that identify trauma survivors at risk of APNS. Such tools could potentially identify at-risk individuals during an early neuroplastic period, when APNS treatments might be most efficacious.\textsuperscript{22–24, 30}

Several clinical prediction tools for PTS have been developed using sociodemographic and self-report data (e.g.\textsuperscript{31–40}). A number of previous studies have also examined the role of genetic and biological factors on APNS risk\textsuperscript{31–51}, overall suggesting that biomarkers may improve risk stratification and/or treatment selection vs. clinical and self-report factors alone. Additionally, identification of blood-based risk biomarkers can provide insight into neurobiologic changes occurring in the early aftermath of trauma exposure that mediate APNS and could identify novel targets for preventative interventions. The purpose of this review is to summarize current literature regarding circulating risk biomarkers of APNS, as well as to examine key considerations and challenges for their discovery and translation. We will also highlight the potential of the AURORA study, a large-scale longitudinal study of trauma survivors that seeks to identify such circulating risk biomarkers.

Circulating biomarkers
The NIH Biomarkers Definitions Working Group defines biomarkers as “characteristics that are objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”\textsuperscript{52}. Continued intensive interest in biomarker identification, together with increasing ambiguity regarding the nomenclature for biomarker subtypes, led the FDA and NIH to develop the
Biomarkers, EndpointS and other Tools (BEST) resource. This initiative seeks to improve communication, align expectations, and improve scientific understanding of biomarkers and created definitions for diagnostic biomarkers and susceptibility (“risk”) biomarkers.

Diagnostic biomarkers are defined as those that detect or confirm the presence of a disease or condition. Such biomarkers are the most common type of blood-based biological markers identified for APNS to-date, and include circulating biomarkers cataloged in the PTSD Biomarker Database. Risk biomarkers are defined as biomarkers that indicate the potential for developing a disease that is not yet clinically apparent. Examples of circulating blood-based biomarkers that have been assessed via previous research as risk factors for APNS are displayed in Figure 1. Of note, genetic polymorphisms and epigenetic factors are also promising biomarkers of APNS, however, these will not be reviewed here as a number of review articles have recently covered this topic.

Summary of current literature

In this review, we surveyed all literature published in NCBI PubMed since its inception and through the end of 2018, using the search strategy provided in Supplementary Figure 1. This search retrieved longitudinal human studies that examined blood-based, circulating biomarkers collected before or proximally to (soon after) trauma exposure that predicted three of the most common APNS outcomes (PTS, depression, and regional or widespread pain) over time. While APNS includes other sequelae (e.g. substance abuse and somatic (“post-concussive”) symptoms), they are not included in this review. In particular, and given our focus on circulating biomarkers, our search strategy a priori selected original research studies that assess hormones, proteins, cell-free DNA (cfDNA), mRNA and non-coding RNAs, immune markers, neuropeptides, and neurotransmitters, and (as noted above) it excluded studies that examined genotypes and epigenetic modifications. A large number of studies have assessed trauma exposure, APNS outcomes, and circulating biomarkers either retrospectively or cross-sectionally; while these studies examine the diagnostic value of putative biomarkers for APNS, they do not determine whether such biomarkers predict risk for APNS outcomes over time. Thus, such biomarkers were excluded from the present review. All articles retrieved were assessed for their appropriateness by two independent raters (SDL and ASZ), and appropriate results were supplemented with any manually identified articles.

Longitudinal studies to date that examine whether circulating biomarkers predict susceptibility or risk for APNS outcomes over time are summarized in Table 1. The majority of this work has focused on PTS symptoms, but studies have also examined depressive symptoms and CMP as primary phenotypic endpoints. Given the well-established role of the hypothalamic-pituitary adrenal axis (HPA) and glucocorticoid signaling in stress-related disease, many studies to date have examined various components of glucocorticoid signaling, including cortisol levels, glucocorticoid sensitivity, glucocorticoid receptor abundance, cortisol awakening response, and mRNA levels of notable glucocorticoid-responsive genes (e.g., FKBP5, GILZ, and SGK1) in whole blood or peripheral blood monocytes (PBMC). Other studies have examined genome-wide mRNA expression in PBMC or leukocytes, microRNA levels and mRNA
expression of X chromosome gene transcripts in whole blood,75, 82 cell-free DNA,83 Vitamin B85, C-reactive protein (CRP),80, 83 proinflammatory cytokines,44, 78, 89 norepinephrine90, and neuropeptides and neurotransmitters including oxytocin, vasopressin, GABA, and neuropeptide Y in either serum or plasma.72, 76, 77, 81 While several (but not all) of these studies have found significant associations between biological markers and longitudinal APNS outcomes, to our knowledge no susceptibility/risk biomarkers have been replicated across research groups. Two studies, however, did observe independent replication across two trauma cohorts84, 88.

Furthermore, and as shown in Table 1 and discussed in the next section, there is considerable heterogeneity in terms of not only the type of biomarker studied but also in the methodological details, the phenotypic outcomes, and the characteristics of trauma exposure examined across studies, rendering cross-study comparisons challenging. Importantly, the type, intensity, duration, and timing of trauma are all likely to involve distinct biological responses and molecular changes potentially emerging at different timepoints following trauma exposure. Disentangling the mechanisms of pleiotropic APNS will be a critical task for future research endeavors and a major contribution towards personalized medicine and psychiatry.

One interesting observation from our literature search is that the risk biomarkers assessed included both those biomolecules that are predominantly considered peripherally acting (e.g. cortisol and inflammatory cytokines) and also those biomolecules that are thought to originate from and play a role in the central nervous system (e.g. GABA, NPY). Multiple reports evaluating PTSD and related outcomes suggest that circulating biomarkers that predict APNS might also reflect neurobiological changes occurring centrally91–95. For example, one study found a substantial overlap between biomarkers identified in post-mortem brain tissue and previously identified blood biomarkers of schizophrenia92. Another study found that gene expression in the blood and brain are comparable96, suggesting that peripheral transcriptional programs can be representative of those in the central nervous system. If it is thought that peripherally detected biomarkers reflecting brain changes are particularly important to risk biomarker discovery for APNS, it might also be useful for researchers in the APNS field to consider examining neuronally derived microvesicles that transport specific biomolecules (e.g. miRNA, siRNA, mRNA) from the brain to peripheral tissues97, 98. These neuronal microvesicles are thought to communicate pathologic brain processes.

**Key methodological considerations**

Characteristics used to evaluate the potential utility of an APNS risk biomarker are summarized in Box 1.99 In Figure 2 we outline key steps in the discovery pipeline of circulating blood-based risk biomarkers of APNS. Careful methodologic design is critical, because small differences in collection, isolation, and quantitation can greatly influence validity and translation. While myriad methodologic decisions must be made for every study, a selection of examples from various stages of the biomarker evaluation process will be presented here, using the evaluation of microRNA (miRNA) as an example.
• **Cohort and participant characteristics:** Perhaps one of the most critical factors influencing biomarker discovery is the quality of the epidemiological study in which biological samples are collected. This is because effect estimates of risk biomarker associations with APNS outcomes can be influenced by both selection biases, e.g. loss to follow-up\(^{100}\), missing data\(^{101}\), sampling bias\(^{102}\) and information biases, e.g. due to interviewer\(^{103}\), recall\(^{104}\), or reporting\(^{105}\) bias. Confounding\(^{106}\) due to various participant characteristics and participant-centered factors (Figure 2) can also influence effect estimates.

• **Biofluid evaluated:** Biofluid selection must balance important trade-offs. For example, the use of serum or plasma (vs. whole blood) when searching for miRNA biomarkers has the advantages of enriching for non-blood based miRNA (such as neuronal-specific miRNA), and miRNA are stable in serum or plasma. However, the majority of miRNA in serum and plasma originate from blood cells (e.g. miR-451, miR-486) and inconsistent processing of serum and plasma can lead to inconsistent levels of these miRNA to be released into the extracellular compartment\(^{107}\).

• **Timing of processing:** Time variation prior to processing (the amount of time that blood sits at room temperature following blood draw) can lead to inconsistent miRNA levels across samples due to ex-vivo transcription, degradation, and red blood cell lysis\(^{108}\). (Of note, plasma proteins are also susceptible to degradation, but might be stable for slightly longer periods of time than plasma based nucleic acids\(^{109,110}\)).

• **Blood collection tube type:** Tube type (e.g., type and amount of anticoagulant) can influence miRNA quantification\(^{111}\).

• **Sample storage:** Sample storage conditions, including storage temperature, number of freeze-thaw cycles, buffer used for storage, and length of time in storage can influence biomarker detection and quantification\(^{112}\).

• **Isolation method:** Methods of isolation and detection of the molecular component can influence biomarker detection. For example, miRNA can be isolated from plasma, serum, or whole blood using a variety of methods including both column-based (e.g. RNeasy kit) and column-free (e.g. Trizol) techniques. These techniques can affect downstream analyses and quantification\(^{113}\) and potential introduction of RNases at this step can degrade isolated miRNA.

• **Detection method:** Different biomarker detection methods have different technical biases that can create cross-method variation\(^{114–118}\). For example, different miRNA library preparation protocols for sequencing have been shown to generate discrepant results\(^{119–121}\). Fortunately, substantial efforts are being made to reduce technical biases\(^{122,123}\). Additionally, due to the predominance of only a few highly abundant circulating biomolecules (e.g. the 22 most abundant circulating proteins account for 99% of the total protein concentration\(^{124}\), and a small handful of miRNAs make up the vast majority of detectable miRNA, the
dynamic range of detection is greatly affected by the choice of processing platform. Therefore, detection methods (e.g. targeted arrays vs sequencing or mass-spectrometry) can influence the sensitivity of detection.

Following successful isolation and quantitation of biomarker data, it is important to perform proper quality control steps, such as examining the full cohort for outliers, technical errors, and batch effects. Quality controlled data is usually then normalized (e.g., for small RNA-seq reads, data normalization is standard, however, the normalization methods are not\textsuperscript{125} and in cases where the data is non-normally distributed, the data is often log transformed. Statistical and/or bioinformatics-based analyses are then applied to assess the relationship between candidate biomarkers and longitudinal APNS outcomes (e.g.,\textsuperscript{126–128}). Important considerations include whether to take a hypothesis-driven vs. a data-driven approach, what factors to adjust for, and whether to perform traditional or machine-learning approaches.

Researchers should also consider whether they wish to develop a “stand-alone” biomarker or a biomarker that is applied in combination with clinical or other factors. Three examples of “stand-alone biomarkers are the FDA-approved RNA expression based tool, PAM50, that assesses risk of breast cancer recurrence\textsuperscript{129}, the microRNA expression based tool, Osteomir, that determines risk for a first fracture in female patients of postmenopausal osteoporosis\textsuperscript{130–132}, and the recent FDA-approved biomarker, Banyan-Brain Trauma Indicator (BTI), which assesses serum levels of two proteins GFAP and UCH-L1, to identify acute intracranial injury\textsuperscript{133}. Perhaps the most well-know combined clinical and blood-based biomarker risk tools are heart disease vulnerability assessments, (e.g.,\textsuperscript{134, 135}) which incorporate epidemiological factors (e.g., age, smoking status) and circulating blood-based biomarkers (e.g., HDL cholesterol, high sensitivity c-reactive protein\textsuperscript{136}). Another approach is to use blood-based biomarkers in a tiered fashion, in which more expensive blood-based biomarkers are only used for individuals in whom epidemiologic and clinical factors alone do not achieve effective discrimination. An example of such a tiered use of biomarkers is current emergency department practice for the evaluation of pulmonary embolism among patients felt to be at low pre-test probability. Among such individuals, a tool using clinical/epidemiologic factors (The PERC rule\textsuperscript{137, 138}) is first applied, and blood testing is only used among individuals in whom pulmonary embolism cannot be reasonably excluded using the PERC rule alone.

**Translation to the clinic**

Once a promising circulating risk biomarker or multi-biomarker signature is identified, it is critical that further development and testing be performed in ways that allow potential translation to clinical practice (see Box 1 and Figure 2 for considerations on early-stage discovery). The Critical Path Initiative is an FDA-led national strategy that aims to improve the way products are developed, tested, and manufactured\textsuperscript{139}. This initative includes the Biomarker Qualification Program (BQP), a part of the FDA’s Center for Drug Evaluation and Research that creates a pathway for translating biomarkers to clinical use by working with researchers or requestors to guide biomarker development. The goal of the BQP is to ensure that the biomarker is: a) suited to a well-defined COU, b) measured reliably and feasibly, and c) adequately performing to support the COU.
One of the first examples of a blood-based risk biomarker that has been accepted into the BQP are pancreatic islet cell autoantibodies as susceptibility/risk biomarkers of future development of Type 1 Diabetes.\textsuperscript{140} While not all biomarkers need to be qualified, it is highly recommended that researchers performing studies that seek to develop risk biomarkers of APNS become familiar with this program. This is because qualifying a biomarker for a specific context of use (COU) improves the value of that biomarker by providing FDA documentation and guidance for use, enables the biomarker to be used in drug development programs specific to the COU, and provides evidence to support its use in clinical trials that identify new therapeutics. Further information can be found at: Biomarker Qualification Program.

Challenges to the discovery of circulating risk biomarkers of APNS

Research efforts that aim to identify susceptibility/risk biomarkers for APNS face several challenges and limitations. First, APNS are vastly heterogeneous diagnostic entities; for example, the categorical diagnosis of PTSD based on DSM-5 has been calculated to comprise 636,120 possible symptom combinations, each meeting diagnostic criteria for the disorder.\textsuperscript{141} These different symptom profiles may also have differences in their potential etiologies and biomarker profiles, thus examining PTSD and other APNS as single diagnostic categories may severely limit our ability to discover reliable biomarkers. However, as the field moves towards a more succinct definition of APNS outcomes that better characterize the full symptom profiles of trauma survivors (versus traditional syndromic classifications studied in isolation)\textsuperscript{4}, we will increase our ability to identify accurate target groups to which blood-based risk biomarkers can more specifically identify vulnerable individuals.

Second, few large-scale longitudinal studies have been performed that track APNS in samples large enough to permit powerful and replicable findings. The importance of large sample sizes when examining neuropsychiatric endpoints is highlighted, for example, by genome-wide association studies, wherein the number of identified hits steadily increases with sample size.\textsuperscript{142–144} However, small high-quality longitudinal cohort studies also have utility to biomarker researchers, as these cohorts can be used to identify risk biomarkers with large predicted effect sizes or to replicate findings from larger cohorts. In the event that a researcher does not have a sample size sufficient for omics based analyses, \textit{in silico} modeling approaches (e.g.\textsuperscript{145, 146}) can also help identify promising candidate biomarkers and thus reduce the number of hypotheses being tested in any single study.

Third, with the exception of studies listed in Table 1, most studies to date are cross-sectional in nature. Cross-sectional studies have limited ability to distinguish between risk/predictive vs. diagnostic biomarkers, to identify temporal changes in blood-based biomarkers after trauma, or to identify outcome trajectories in which risk biomarkers could accurately identify the long-term course of APNS symptoms following trauma exposure.

Fourth, previous studies have largely focused on single biological measures that are known to be influenced by a great many factors in addition to stress exposure. An example is cortisol, a commonly used marker that can be greatly influenced by factors such circadian
and ultradian rhythmicity, age, and sex. One area of current research is evaluating whether increased accuracy can be achieved by combining cortisol or other specific biological measures with additional biological factors or with sociodemographic factors (e.g.,). Finally, as described above, methodological/technical hurdles are present at each step of biomarker assessment, which threaten identification and/or replication. These myriad hurdles underscore the need for both technical and biological validation of findings.

The promise of the AURORA study to identify circulating risk biomarkers of APNS

The AURORA (Advancing Understanding of Recovery after Trauma) study is a publicly funded large-scale (n = 5,000 target cohort) Emergency Department-based prospective study of APNS development following trauma exposure. Study participants are enrolled in the early aftermath of trauma exposure and undergo multi-layered, cross-disciplinary assessments over the course of one year. These assessments include neurocognitive, self-report, physiological, digital phenotype, psychophysiological, neuroimaging, and genomic assessments. Using this data, AURORA investigators and other individuals in the research community can improve outcome phenotypes, develop prediction tools, and improve understanding of molecular mechanisms driving APNS. For a more detailed description of the full study, please refer to the AURORA methods paper.

Towards the goal of identifying circulating risk biomarkers, biological specimens (RNA PAXgene, and EDTA-plasma) are collected in the Emergency Department from all AURORA participants and at two weeks and six months from a subset of study participants that also complete neuroimaging and psychophysical assessments (target n=800 participants at each timepoint) (Figure 3). Blood specimens are also collected at the six month timepoint from a further subset of study participants (target n=2,200 individuals). Other biological specimens including DNA PAXgene tubes (for genotyping and methylation analyses) are also collected throughout the study.

All specimens are processed immediately after collection and stored at −80°C until batch shipment to the National Institute of Mental Health Repository and Genomics Resources (NIMH RGR) for long-term storage. Assessments of specimen quality occurs continuously throughout the study to ensure standardization (e.g., plasma processing procedures, timing of blood draw and freezing, adequate blood volume). Importantly, these samples (n=88,000 total tubes including each 250μl plasma aliquot) and all AURORA data will be available to the broader scientific community after Fall 2022.

Biological specimens for the AURORA study are collected in the very early aftermath of trauma exposure (usually within 24 hours), and APNS outcome measures are assessed over the course of a year. Therefore, circulating biomarker levels can be incorporated into traditional statistical models and contemporary machine learning algorithms that assess the predictive accuracy of biological molecules, ratios or signatures in isolation or concomitantly with additional AURORA study data from other research domains in
identifying risk of APNS trajectories and multidimensional outcomes. Because biological specimens are also collected in many participants at multiple timepoints, how circulating biomarkers change over APNS developmental or recovery trajectories can also be assessed.

Conclusions

In this literature review, we identified twenty-three studies that assessed circulating risk biomarkers of APNS. Eighty three percent of the identified studies were published in the past ten years. This recent increase in attention to the identification of APNS risk biomarkers, along with multiple recent efforts aimed at increased biomarker discovery (e.g. the FDA BQP, PTSD Biomarker Database, and AURORA Study), marks an exciting time for research in this field. This increased trajectory, together with continued methodologic advances, provide hope that the next decade will see substantial advances towards the goal of objectively identifying at-risk individuals and gaining insight into pathophysiologic mechanisms. However, these years will not be without immense challenges, especially those challenges related to methodological complexities of biomarker collection, processing, and analysis, integration of diverse efforts across laboratories and studies, replication across cohorts, and translation of our discoveries from the bench to bedside. While these research efforts are challenging, with a collaborative and thoughtful research process the future for circulating risk biomarker discovery for APNS is bright.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements and Disclosures:

We acknowledge Elizabeth Moreton and Michelle Cawley from the University of North Carolina Health Sciences Library for support in performing the literature search for this review article. SDL is supported by NIH K01AR071504, SAM is supported by NIH R01AR064700 and U01MH110925, KCK is supported by NIH R01MH106595, R01MH101269, U01MH110925, and T32MH017119, KJR is supported by NIH U01MH110925, R01MH071537, R01MH094757 and R01MH106595.

References

1. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system Current protocols in molecular biology 2011; Chapter 25: Unit25B.10.
2. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. Journal of traumatic stress 2013; 26(5): 537–547. [PubMed: 24151000]
3. Eastel JM, Lam KW, Lee NL, Lok WY, Tsang AHF, Pei XM et al. Application of NanoString technologies in companion diagnostic development. Expert review of molecular diagnostics 2019; 19(7): 591–598. [PubMed: 31164012]
4. McLean SA, Ressler K, Koenen KC, Neylan T, Germine L, Jovanovic T et al. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. Molecular Psychiatry 2019.
5. Gaskin DJ, Richard P. The Economic Costs of Pain in the United States. The Journal of Pain 2012; 13(8): 715–724. [PubMed: 22607834]
6. Dobie DJ, Kivlahan DR, Maynard C, Bush KR, Davis TM, Bradley KA. Posttraumatic stress disorder in female veterans: association with self-reported health problems and functional impairment. Archives of internal medicine 2004; 164(4): 394–400. [PubMed: 14980990]
7. Outcalt SD, Kroenke K, Krebs EE, Chumbler NR, Wu J, Yu Z et al. Chronic pain and comorbid mental health conditions: independent associations of posttraumatic stress disorder and depression with pain, disability, and quality of life. Journal of behavioral medicine 2015; 38(3): 535–543. [PubMed: 25786741]

8. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. The Journal of clinical psychiatry 2000.

9. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. Journal of occupational and environmental medicine 2003; 45: 3135–3144. [PubMed: 12813119]

10. Bleich A, Solomon Z. Evaluation of psychiatric disability in PTSD of military origin. Isr J Psychiatry Relat Sci 2004; 41: 268–276. [PubMed: 15941022]

11. McNally RJ, Frueh BC. Why are Iraq and Afghanistan War veterans seeking PTSD disability compensation at unprecedented rates? Journal of anxiety disorders 2013; 27(5): 520–526. [PubMed: 23954726]

12. Suriš A, Lind L. Military sexual trauma: A review of prevalence and associated health consequences in veterans. Trauma, Violence, & Abuse 2008; 9(4): 250–269.

13. Lew HL, Otis JD, Tun C, Kerns RD, Clark ME, Cifu DX. Prevalence of chronic pain, posttraumatic stress disorder, and persistent postconcussive symptoms in OIF/OEF veterans: polytrauma clinical triad. Journal of Rehabilitation Research & Development 2009; 46(6).

14. Haskell SG, Gordon KS, Mattocks K, Duggal M, Erdos J, Justice A et al. Gender differences in rates of depression, PTSD, pain, obesity, and military sexual trauma among combat veterans of Iraq and Afghanistan. Journal of Women’s Health 2010; 19(2): 267–271.

15. Simon R Sensitivity, specificity, PPV, and NPV for predictive biomarkers. JNCI: Journal of the National Cancer Institute 2015; 107(8).

16. Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clinical chemistry 2016; 62(5): 737–742. [PubMed: 27001493]

17. Régnier M-A, Raux M, Le Manach Y, Asencio Y, Gaillard J, Devilliers C et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology: The Journal of the American Society of Anesthesiologists 2012; 117(6): 1276–1288.

18. Guyette F, Suffoletto B, Castillo J-L, Quintero J, Callaway C, Puyana J-C. Prehospital serum lactate as a predictor of outcomes in trauma patients: a retrospective observational study. Journal of Trauma and Acute Care Surgery 2011; 70(4): 782–786.

19. Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. The Journal of trauma 1993; 35(4): 584–588; discussion 588–589. [PubMed: 8411283]

20. Boateng D, Agyemang C, Beune E, Meeks K, Smeeth L, Schulze MB et al. Cardiovascular disease risk prediction in sub-Saharan African populations—Comparative analysis of risk algorithms in the RODAM study. International journal of cardiology 2018; 254: 310–315. [PubMed: 29407113]

21. Kearns MC, Ressler KJ, Zatzick D, Rothbaum BO. Early interventions for PTSD: a review. Depression and anxiety 2012; 29(10): 833–842. [PubMed: 22941845]

22. Shalet A, Ankri Y, Adessky R, Qian M et al. Long-term outcome of early interventions to prevent posttraumatic stress disorder. The Journal of clinical psychiatry 2016; 77(5): e580–587. [PubMed: 27135249]

23. Fritz JM, Magel JS, McFadden M, Asche C, Thackeray A, Meier W et al. Early physical therapy vs usual care in patients with recent-onset low back pain: a randomized clinical trial. Jama 2015; 314(14): 1459–1467. [PubMed: 26461996]

24. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. The Lancet Psychiatry 2016; 3(2): 171–178. [PubMed: 26851330]

25. McGeary D, Moore M, Vriend CA, Peterson AL, Gatchel RJ. The evaluation and treatment of comorbid pain and PTSD in a military setting: an overview. Journal of clinical psychology in medical settings 2011; 18(2): 155. [PubMed: 21626356]

Mol Psychiatry. Author manuscript; available in PMC 2020 September 11.
27. Feuerstein M, Berkowitz SM, Peck CA Jr. Musculoskeletal-related disability in US Army personnel: prevalence, gender, and military occupational specialties. Journal of occupational and environmental medicine 1997; 39(1): 68–78. [PubMed: 9029434]

28. Rutherford EJ, Morris JJ, Reed GW, Hall KS. Base deficit stratifies mortality and determines therapy. The Journal of trauma 1992; 33(3): 417–423. [PubMed: 1404512]

29. Kincaid EH, Miller PR, Meredith JW, Rahman N, Chang MC. Elevated arterial base deficit in trauma patients: a marker of impaired oxygen utilization. Journal of the American College of Surgeons 1998; 187(4): 384–392. [PubMed: 9783784]

30. Litz BT, Gray MJ, Bryant RA, Adler AB. Early intervention for trauma: Current status and future directions. Clinical psychology: science and practice 2002; 9(2): 112–134.

31. Kleim B, Ehlers A, Glucksmann E. Early predictors of chronic post-traumatic stress disorder in assault survivors. Psychological medicine 2007; 37(10): 1457–1467. [PubMed: 17588274]

32. Kessler RC, Rose S, Koenen KC, Karam EG, Stang PE, Stein DJ et al. How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys. World Psychiatry 2014; 13(3): 265–274. [PubMed: 25273300]

33. Karstoft K-I, Statnikov A, Andersen SB, Madsen T, Galatzer-Levy IR. Early identification of posttraumatic stress following military deployment: Application of machine learning methods to a prospective study of Danish soldiers. Journal of affective disorders 2015; 184: 170–175. [PubMed: 26093830]

34. Powers MB, Warren AM, Rosenfield D, Roden-Foreman K, Bennett M, Reynolds MC et al. Predictors of PTSD symptoms in adults admitted to a Level I trauma center: a prospective analysis. Journal of anxiety disorders 2014; 28(3): 301–309. [PubMed: 24632075]

35. Symes L, Maddoux J, McFarlane J, Pennings J. A risk assessment tool to predict sustained PTSD symptoms among women reporting abuse. Journal of Women’s Health 2016; 25(4): 340–347.

36. Rosellini AJ, Dussaillant F, Zubizarreta JR, Kessler RC, Rose S. Predicting posttraumatic stress disorder following a natural disaster. Journal of psychiatric research 2018; 96: 15–22. [PubMed: 28950110]

37. Galatzer-Levy IR, Karstoft KI, Statnikov A, Shalev AY. Quantitative forecasting of PTSD from early trauma responses: a Machine Learning application. Journal of psychiatric research 2014; 59: 68–76. [PubMed: 25260752]

38. Karstoft KI, Galatzer-Levy IR, Statnikov A, Li Z, Shalev AY. Bridging a translational gap: using machine learning to improve the prediction of PTSD. BMC psychiatry 2015; 15; 30. [PubMed: 25886446]

39. Shalev AY, Gevonden M, Ratanatharathorn A, Laska E, van der Mei WF, Qi W et al. Estimating the risk of PTSD in recent trauma survivors: results of the International Consortium to Predict PTSD (ICPP). World Psychiatry 2019; 18(1): 77–87. [PubMed: 30600620]

40. Freedman SA, Brandes D, Peri T, Shalev A. Predictors of chronic post-traumatic stress disorder. A prospective study. The British journal of psychiatry : the journal of mental science 1999; 174: 353–359. [PubMed: 10533555]

41. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychological bulletin 2007; 133(4): 581. [PubMed: 17592957]

42. Yehuda R Biology of posttraumatic stress disorder. The Journal of clinical psychiatry 2001.

43. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. American Journal of Psychiatry 2010; 167(11): 1305–1320. [PubMed: 20843874]

44. Michopoulos V, Beurel E, Gould F, Dhabhar FS, Schultebraucks K, Galatzer-Levy I et al. Association of Prospective Risk for Chronic PTSD Symptoms With Low TNFalpha and IFNgamma Concentrations in the Immediate Aftermath of Trauma Exposure. The American journal of psychiatry 2019: appiajp201919010039.

45. Stevens JS, Kim YJ, Galatzer-Levy IR, Reddy R, Ely TD, Nemeroff CB et al. Amygdala Reactivity and Anterior Cingulate Habitation Predict Posttraumatic Stress Disorder Symptom Maintenance After Acute Civilian Trauma. Biological psychiatry 2017; 81(12): 1023–1029. [PubMed: 28117048]
46. Galatzner-Levy IR, Ma S, Statnikov A, Yehuda R, Shalev AY. Utilization of machine learning for prediction of post-traumatic stress: a re-examination of cortisol in the prediction and pathways to non-remitting PTSD. Translational psychiatry 2017; 7(3): e0. [PubMed: 28323285]

47. Hinrichs R, van Rooij SJ, Michopoulos V, Schultebraucks K, Winters S, Maples-Keller J et al. Increased Skin Conductance Response in the Immediate Aftermath of Trauma Predicts PTSD Risk. Chronic Stress (Thousand Oaks) 2019; 3.

48. Bonne O, Brandes D, Gilboa A, Gomori JM, Shenton ME, Pitman RK et al. Longitudinal MRI study of hippocampal volume in trauma survivors with PTSD. The American journal of psychiatry 2001; 158(8): 1248–1251. [PubMed: 11481158]

49. Shalev AY, Sahar T, Freedman S, Peri T, Glick N, Brandes D et al. A prospective study of heart rate response following trauma and the subsequent development of posttraumatic stress disorder. Archives of general psychiatry 1998; 55(6): 553–559. [PubMed: 9633675]

50. Yehuda R, McFarlane AC, Shalev AY. Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event. Biological psychiatry 1998; 44(12): 1305–1313. [PubMed: 9861473]

51. Shalev AY, Peri T, Brandes D, Freedman S, Orr SP, Pitman RK. Auditory startle response in trauma survivors with posttraumatic stress disorder: a prospective study. The American journal of psychiatry 2000; 157(2): 255–261. [PubMed: 10671396]

52. Group BDW, Atkinson AJ Jr, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology & therapeutics 2001; 69(3): 89–95. [PubMed: 11240971]

53. Michopoulos V, Northholm SD, Jovanovic T. Diagnostic biomarkers for posttraumatic stress disorder: promising horizons from translational neuroscience research. Biological psychiatry 2015; 78(5): 344–353. [PubMed: 25727177]

54. Tracey I, Woolf CJ, Andrews NA. Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment. Neuron 2019; 101(5): 783–800. [PubMed: 30844399]

55. Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatric disease and treatment 2017; 13: 1245. [PubMed: 28546750]

56. Domingo-Fernandez D, Provost A, Marin-Llao J, Lasseter H, Diaz K, Daskalakis N et al. PTSD Biomarker Database: Deep Dive Meta-database for PTSD Biomarkers, Visualizations, and Analysis Tools. BioRxiv 2019: 547901.

57. Blacker CJ, Frye MA, Morava-Kozicz E, Kozicz T, Veldic M. A review of epigenetics of PTSD in comorbid psychiatric conditions. Genes 2019; 10(2): 140.

58. Sharma S, Ressler KJ. Genomic updates in understanding PTSD. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2018.

59. Nievergelt CM, Ashley-Koch AE, Dalvie S, Hauser MA, Morey RA, Smith AK et al. Genomic approaches to posttraumatic stress disorder: the psychiatric genomic consortium initiative. Biological psychiatry 2018; 83(10): 831–839. [PubMed: 29555185]

60. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W. Genetic architecture of human pain perception. TRENDS in Genetics 2007; 23(12): 605–613. [PubMed: 18023497]

61. Young EE, Lariviere WR, Belfer I. Genetic basis of pain variability: recent advances. Journal of medical genetics 2012; 49(1): 1–9. [PubMed: 22058430]

62. Descalzi G, Ikegami D, Usijima T, Nestler EJ, Zachariou V, Narita M. Epigenetic mechanisms of chronic pain. Trends in neurosciences 2015; 38(4): 237–246. [PubMed: 25765319]

63. Nestler EJ. Epigenetic mechanisms of depression. JAMA psychiatry 2014; 71(4): 454–456. [PubMed: 24499927]

64. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. American Journal of Psychiatry 2000; 157(10): 1552–1562. [PubMed: 11007705]

65. Zannas AS, Provençal N, Binder EB. Epigenetics of posttraumatic stress disorder: current evidence, challenges, and future directions. Biological psychiatry 2015; 78(5): 327–335. [PubMed: 25979620]

66. Zannas AS, Binder E. and Mehta D. Genomics of PTSD. Posttraumatic Stress Disorder 2016.
67. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, Shalev AY. Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. Molecular psychiatry 2005; 10(5): 500–513, 425. [PubMed: 15685253]

68. van Zuiden M, Geuze E, Willemen HL, Vermetten E, Maas M, Heijnen CJ et al. Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. The American journal of psychiatry 2011; 168(1): 89–96. [PubMed: 21078706]

69. van Zuiden M, Geuze E, Willemen HL, Vermetten E, Maas M, Amarouchi K et al. Glucocorticoid receptor pathway components predict posttraumatic stress disorder symptom development: a prospective study. Biological psychiatry 2012; 71(4): 309–316. [PubMed: 22137507]

70. Glatt SJ, Tylee DS, Chandler SD, Pazol J, Niervergelt CM, Woekl CH et al. Blood-based gene-expression predictors of PTSD risk and resilience among deployed marines: a pilot study. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2013; 162b(4): 313–326.

71. van Zuiden M, Kavelaars A, Vermetten E, Olff M, Geuze E, Heijnen C. Pre-deployment differences in glucocorticoid sensitivity of leukocytes in soldiers developing symptoms of PTSD, depression or fatigue persist after return from military deployment. Psychoneuroendocrinology 2015; 51: 513–524. [PubMed: 25277845]

72. Reijnen A, Geuze E, Vermetten E. Individual variation in plasma oxytocin and vasopressin levels in relation to the development of combat-related PTSD in a large military cohort. Journal of psychiatric research 2017; 94: 88–95. [PubMed: 28689067]

73. Walsh K, Nugent NR, Kotte A, Amstadler AB, Wang S, Guille C et al. Cortisol at the emergency room rape visit as a predictor of PTSD and depression symptoms over time. Psychoneuroendocrinology 2013; 38(11): 2520–2528. [PubMed: 23806832]

74. van Zuiden M, Heijnen CJ, Maas M, Amarouchi K, Vermetten E, Geuze E et al. Glucocorticoid sensitivity of leukocytes predicts PTSD, depressive and fatigue symptoms after military deployment: A prospective study. Psychoneuroendocrinology 2012; 37(11): 1822–1836. [PubMed: 22503138]

75. Yu S, Chen C, Pan Y, Kurz MC, Datner E, Hendry PL et al. Genes known to escape X chromosome inactivation predict co-morbid chronic musculoskeletal pain and posttraumatic stress symptom development in women following trauma exposure. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2018.

76. Vaiva G, Boss V, Ducrocq F, Fontaine M, Devos P, Brunet A et al. Relationship between posttrauma GABA plasma levels and PTSD at 1-year follow-up. The American journal of psychiatry 2006; 163(8): 1446–1448. [PubMed: 16877663]

77. Reijnen A, Geuze E, Eekhout I, Maihofer AX, Nievergelt CM, Baker DG et al. Biological profiling of plasma neuropeptide Y in relation to posttraumatic stress symptoms in two combat cohorts. Biol Psy chol 2018; 134: 72–79. [PubMed: 29471015]

78. Cohen M, Meir T, Klein E, Volpin G, Assaf M, Pollack S. Cytokine levels as potential biomarkers for predicting the development of posttraumatic stress symptoms in casualties of accidents. International journal of psychiatry in medicine 2011; 42(2): 117–131. [PubMed: 22409092]

79. Inslicht SS, Otte C, McCaslin SE, Apfel BA, Henn-Haase C, Metzler T et al. Cortisol awakening response prospectively predicts peritraumatic and acute stress reactions in police officers. Biol Psychiatry 2011; 70(11): 1055–1062. [PubMed: 21906725]

80. Eraly SA, Nievergelt CM, Maihofer AX, Barkauskas DA, Biswas N, Agorastos A et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 2014; 71(4): 423–431. [PubMed: 24576974]

81. Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P et al. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry 2004; 55(3): 250–254. [PubMed: 14744465]

82. Linnstaedt SD, Walker MG, Parker JS, Yeh E, Sons RL, Zimny E et al. MicroRNA circulating in the early aftermath of motor vehicle collision predict persistent pain development and suggest a role for microRNA in sex-specific pain differences. Mol Pain 2015; 11: 66. [PubMed: 26498117]
83. Rushton AB, Evans DW, Middlebrook N, Heneghan NR, Small C, Lord J et al. Development of a screening tool to predict the risk of chronic pain and disability following musculoskeletal trauma: protocol for a prospective observational study in the United Kingdom. BMJ open 2018; 8(4): e017876.

84. Linnstaedt SD, Rueckeis CA, Riker KD, Pan Y, Wu A, Yu S et al. microRNA-19b predicts widespread pain and posttraumatic stress symptom risk in a sex-dependent manner following trauma exposure. Pain 2019.

85. Mauck MC, Linnstaedt SD, Bortsov A, Kurz M, Hendry PL, Lewandowski C et al. Vitamin D insufficiency increases risk of chronic pain among African Americans experiencing motor vehicle collision. Pain 2019.

86. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA : the journal of the American Medical Association 1992; 267(9): 1244–1252. [PubMed: 1538563]

87. Gassen NC, Chrousos GP, Binder EB, Zannas AS. Life stress, glucocorticoid signaling, and the aging epigenome: Implications for aging-related diseases. Neurosci Biobehav Rev 2016.

88. Breen MS, Maihofer AX, Glatt SJ, Tylee DS, Chandler SD, Tsuang MT et al. Gene networks specific for innate immune define post-traumatic stress disorder. Mol Psychiatry 2015; 20(12): 1538–1545. [PubMed: 25754082]

89. Pervanidou P, Kolaitis G, Charitaki S, Margeli A, Ferentinos S, Bakoula C et al. Elevated morning serum interleukin (IL)-6 or evening salivary cortisol concentrations predict posttraumatic stress disorder in children and adolescents six months after a motor vehicle accident. Psychoneuroendocrinology 2007; 32(8–10): 991–999. [PubMed: 17825995]

90. Gandubert C, Scali J, Ancelin ML, Carriere I, Dupuy AM, Bagnolini G et al. Biological and psychological predictors of posttraumatic stress disorder onset and chronicity. A one-year prospective study. Neurobiol Stress 2016; 3: 61–67. [PubMed: 27981178]

91. Andrews JA, Neises KD. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. Journal of neurochemistry 2012; 120(1): 26–36. [PubMed: 22017326]

92. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PloS one 2012; 7(10): e46368. [PubMed: 23118852]

93. Milivojevic V, Sinha R. Central and peripheral biomarkers of stress response for addiction risk and relapse vulnerability. Trends in molecular medicine 2018; 24(2): 173–186. [PubMed: 29396148]

94. M L Kelso, J H Oestreich. Traumatic brain injury: Central and peripheral role of α7 nicotinic acetylcholine receptors. Current drug targets 2012; 13(5): 631–636. [PubMed: 22300031]

95. Yubero-Lahoz S, Robledo P, Farré M, de La Torre R. Platelet SERT as a peripheral biomarker of serotonergic neurotransmission in the central nervous system. Current medicinal chemistry 2013; 20(11): 1382–1396. [PubMed: 23409709]

96. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2006; 141(3): 261–268.

97. Simeoli R, Montague K, Jones HR, Castaldi L, Chambers D, Kelleher JH et al. Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma. Nature communications 2017; 8(1): 1778.

98. Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Frontiers in neuroscience 2017; 11: 278. [PubMed: 28588440]

99. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature biotechnology 2006; 24(8): 971.

100. Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is too much? European journal of epidemiology 2004; 19(8): 751–760. [PubMed: 15469032]

101. Gorelick MH. Bias arising from missing data in predictive models. Journal of clinical epidemiology 2006; 59(10): 1115–1123. [PubMed: 16980153]

102. Kleinbaum DG, Morgenstern H, Kupper LL. Selection bias in epidemiologic studies. American Journal of Epidemiology 1981; 113(4): 452–463. [PubMed: 6971055]
103. Tripepi G, Jager K, Dekker F, Wanner C, Zoccali C. Bias in clinical research. Kidney international 2008; 73(2): 148–153. [PubMed: 17978812]

104. Coughlin SS. Recall bias in epidemiologic studies. Journal of clinical epidemiology 1990; 43(1): 87–91. [PubMed: 2319285]

105. Fisher RJ. Social desirability bias and the validity of indirect questioning. Journal of consumer research 1993; 20(2): 303–315.

106. Miettinen OS, Cook EF. Confounding: essence and detection. American journal of epidemiology 1981; 114(4): 593–603. [PubMed: 7304589]

107. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PloS one 2013; 8(6): e64795. [PubMed: 23762257]

108. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N et al. Haemolysis during sample preparation alters microRNA content of plasma. PloS one 2011; 6(9): e24145. [PubMed: 21909417]

109. Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clinical chemistry 2002; 48(10): 1781–1784. [PubMed: 12324497]

110. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clinical chemistry 2003; 49(4): 650–652. [PubMed: 12651819]

111. Kim D-J, Linnstaedt S, Palma J, Park JC, Ntivalas E, Kwak-Kim JY et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. The Journal of Molecular Diagnostics 2012; 14(1): 71–80. [PubMed: 22154918]

112. Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochemical and biophysical research communications 2009; 390(1): 1–4. [PubMed: 19769940]

113. Podolska A, Kaczkowski B, Litman T, Fredholm M, Cirera S. How the RNA isolation method can affect microRNA microarray results. Acta Biochimica Polonica 2011; 58(4).

114. Yeung D, Ciotti S, Purushothama S, Gharahkani E, Kuesters G, Schlain B et al. Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum. J Immunol Methods 2016; 437: 53–63. [PubMed: 2755238]

115. Polaskova V, Kapur A, Khan A, Molloy MP, Baker MS. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 2010; 31(3): 471–482. [PubMed: 20119956]

116. Percy AJ, Chambers AG, Yang J, Domanski D, Borchers CH. Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins. Anal Bioanal Chem 2012; 404(4): 1089–1101. [PubMed: 22547352]

117. Kroot JJ, Kemna EH, Bansal SS, Bushbridge M, Campostrini N, Girelli D et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94(12): 1748–1752. [PubMed: 19996119]

118. Dorgan JF, Fears TR, McMahon RP, Aronson Friedman L, Patterson BH, Greenhut SF. Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. Steroids 2002; 67(3–4): 151–158. [PubMed: 11856538]

119. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nature Reviews Genetics 2012; 13(5): 358.

120. Tian G, Yin X, Luo H, Xu X, Bolund L, Zhang X. Sequencing bias: comparison of different protocols of microRNA library construction. BMC biotechnology 2010; 10(1): 64. [PubMed: 20815927]

121. Hafner M, Renwick N, Brown M, Mihailović A, Holoch D, Lin C et al. RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. Rna 2011; 17(9): 1697–1712. [PubMed: 21775473]

122. Baran-Gale J, Kurtz CL, Erdos MR, Sison C, Young A, Fannin EE et al. Addressing bias in small RNA library preparation for sequencing: a new protocol recovers microRNAs that evade capture by current methods. Frontiers in genetics 2015; 6: 352. [PubMed: 26734062]
123. Sorefan K, Pais H, Hall AE, Kozomara A, Griffiths-Jones S, Moulton V et al. Reducing ligation bias of small RNAs in libraries for next generation sequencing. Silence 2012; 3(1): 4. [PubMed: 22647250]

124. Orton DJ, Doucette AA. Proteomic workflows for biomarker identification using mass spectrometry—technical and statistical considerations during initial discovery. Proteomes 2013; 1(2): 109–127. [PubMed: 28250400]

125. Bullard JH, Purdom E, Hansen KD, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC bioinformatics 2010; 11(1): 94. [PubMed: 20167110]

126. Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004; 5(6): 709–719. [PubMed: 15335291]

127. Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology 2010; 112(4): 1023–1040. [PubMed: 20234303]

128. McDermott JE, Wang J, Mitchell H, Webb-Robertson BJ, Hafen R, Ramey J et al. Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data. Expert opinion on medical diagnostics 2013; 7(1): 37–51. [PubMed: 2335946]

129. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer. Clinical cancer research 2010; 16(21): 5222–5232. [PubMed: 20837693]

130. Heilmeier U, Hackl M, Skalicky S, Weilner S, Schroeder F, Vierlinger K et al. Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2016; 31(12): 2173–2192.

131. Hackl M, Heilmeier U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases - Complex signatures for multifactorial diseases? Mol Cell Endocrinol 2016; 432: 83–95. [PubMed: 26525415]

132. Kocijan R, Muschitz C, Geiger E, Skalicky S, Baierl A, Dormann R et al. Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Frailty Fractures. The Journal of clinical endocrinology and metabolism 2016; 101(11): 4125–4134. [PubMed: 27552543]

133. Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V et al. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. The Lancet Neurology 2018; 17(9): 782–789. [PubMed: 30054151]

134. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837–1847. [PubMed: 9603539]

135. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. Jama 2009; 302(21): 2345–2352. [PubMed: 19952321]

136. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama 2007; 297(6): 611–619. [PubMed: 17299196]

137. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. Journal of thrombosis and haemostasis : JTH 2004; 2(8): 1247–1255. [PubMed: 15304025]

138. Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. Journal of thrombosis and haemostasis : JTH 2008; 6(5): 772–780. [PubMed: 18318689]

139. FDA Critical Path Opportunities Report. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products: [http://wayback.archive-it.org/7993/20180125032208/](http://wayback.archive-it.org/7993/20180125032208/)
140. C-Path. Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative. https://c-path.org/critical-path-institute-encouraged-by-fda-to-move-forward-on-type-1-diabetes-biomarker-initiative/, December 18, 2018.

141. Galatzer-Levy IR, Bryant RA. 636,120 Ways to Have Posttraumatic Stress Disorder. Perspect Psychol Sci 2013; 8(6): 651–662. [PubMed: 26173229]

142. Flint J, Munafo M. Schizophrenia: genesis of a complex disease. Nature 2014; 511(7510): 412–413. [PubMed: 25056056]

143. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoue A et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature genetics 2018; 50(5): 668–681. [PubMed: 29700475]

144. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511(7510): 421–427. [PubMed: 25056061]

145. Siekmeier PJ. An in Silico, Biomarker-Based Method for the Evaluation of Virtual Neuropsychiatric Drug Effects. Neural computation 2017; 29(4): 1021–1052. [PubMed: 28181877]

146. Lin Y, Qian F, Shen L, Chen F, Chen J, Shen B. Computer-aided biomarker discovery for precision medicine: data resources, models and applications. Briefings in Bioinformatics 2017; 20(3): 952–975.

147. Bhake RC, Leendertz JA, Linthorst AC, Lightman SL. Automated 24-hours sampling of subcutaneous tissue free cortisol in humans. Journal of medical engineering & technology 2013; 37(3): 180–184. [PubMed: 23547774]

148. Wust S, Federenko IS, van Rossum EF, Koper JW, Hellhammer DH. Habituation of cortisol responses to repeated psychosocial stress: further characterization and impact of genetic factors. Psychoneuroendocrinology 2005; 30(2): 199–211. [PubMed: 15471617]

149. Galatzer-Levy I, Ma S, Statnikov A, Yehuda R, Shalev A. Utilization of machine learning for prediction of post-traumatic stress: a re-examination of cortisol in the prediction and pathways to non-remitting PTSD. Translational psychiatry 2017; 7(3): e1070.

150. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013; 9(2): 280–299. [PubMed: 23543913]
Box 1.

Ten characteristics of an ideal circulating blood-based susceptibility/risk biomarker of APNS, adapted from the FDA Biomarker Qualification Program and previously published literature, as indicated.

**Biofluid collection is feasible.**

Collection of biofluids should be feasible in care settings where individuals report following trauma (e.g. the emergency department), should be quick to collect, and collection should be minimally invasive. Whole blood, serum, and plasma are examples of such biofluids.

**Biomarker measurement is feasible.**

There should be one or more publicly accessible assays for measuring the biomarker, with potential for translation to clinically used, FDA approved assays/platforms, e.g. ELISA for protein quantification or Nanostring nCounter for RNA expression measurements.

**Biomarker measurement is reliable.**

Test-retest reliability and reproducibility should meet assay analytical performance requirements acceptable to the FDA.

**Context of use (COU) is clearly defined.**

The context of use is a concise description of the biomarker’s specified use. For example, a susceptibility/risk biomarker for APNS development would need to be indexed to a specific population (e.g. age of individuals, sex, ethnicity), a specific outcome (e.g. does the biomarker assess risk for PTS, depression, and CMP, just one of those outcomes, etc), and a specific timeframe of effectiveness (e.g. is it only useful if measured within the first 24 hours of trauma exposure, or can it be measured outside of that timeframe). A more thorough guideline for defining COU can be found here: FDA COU

**Biomarker assesses risk of APNS development both sensitively and specifically.**

These performance measures, along with positive predictive values and negative predictive values should be carefully measured and considered in the context of clinical utility. For example, for APNS risk assessment it might be more acceptable to have a biomarker with more false positives than false negatives if the treatment regimen is low risk (e.g. cognitive behavioral therapy for PTS), whereas it might be more acceptable to have a biomarker with increased false negatives if the treatment regimen is high risk (e.g. long-term opioid therapy for CMP) or is expensive.

**Biomarker consistently identifies at-risk individuals across ethnicities and sexes.**

Recent evidence indicates that longstanding risk tools such as those predicting cardiovascular disease are limited in their ability to assess risk across varied ethnicities. Therefore, biomarker discovery should be performed independent of these factors or should specifically stratify on these factors and clarify this limitation in the COU.
Analytical performance adequately supports COU.
Measurement of a biomarker’s technical performance and clinical utility should support the defined COU.

Biomarker test results can be generated rapidly.
Rapid assays facilitate the ability to risk stratify early after trauma exposure such that interventions can be administered when potentially most efficacious6, 13, 14, 22–27. Rapid test results also improve patient satisfaction.

Measurement of the biomarker is inexpensive.
Concerted efforts should be made to prioritize low-cost biomarkers over high-cost biomarkers in order to improve access to care for all individuals.

Biomarker discovery studies should translate between human and animal.
Parallel evidence in humans and in appropriate models of APNS is important in order to further elucidate details about the biomarker that might not be feasible in human studies. For example, animal studies might enable granular resolution of the timing of increased/decreased levels of the biomarker, extrapolation of results to gain insights into neurobiology of nervous system tissue, and in assessing the utility of the biomarker in other settings such as in drug discovery efforts to identify novel therapeutics that prevent APNS.
Circulating blood-based risk biomarkers that have been assessed in previous studies for their ability to predict the development of adverse posttraumatic neuropsychiatric sequelae (APNS). General categories for these risk biomarkers include hormones, proteins, immune mediators, nucleic acids, and neuropeptides and neurotransmitters. Note that not all circulating risk biomarkers that have been examined to date showed a statistically significantly relationship with APNS. See Table 1 for more details. Validation of the significantly associated risk biomarkers and identification of novel circulating risk biomarkers within the described categories or outside of these categories (e.g. metabolites, microvesicles, immune cells) will be a high priority for APNS-focused researchers in the coming years.
Figure 2.
Key steps (top) and methodological considerations (bottom) in the discovery of circulating blood-based risk biomarkers of adverse posttraumatic neuropsychiatric sequelae (APNS). While the steps and considerations included in this figure are not exhaustive, it represents a subset of the myriad factors that can influence blood based biomarker discovery and translation. For instance, the epidemiological design of the cohort from which samples are drawn, and characteristics/factors of participants can determine whether there is sufficient statistical power to detect a risk biomarker, whether adjustors should be included in statistical models and whether the findings are generalizable to additional populations. SES = socioeconomic status, FDA = U.S. Food and Drug Administration. Adapted from a variety of sources including.\(^99, 119, 150\)
Figure 3.
The AURORA study is an on-going longitudinal cohort study assessing APNS development following trauma exposure. Individuals are enrolled in the Emergency Department and followed over the course of a year. Consistent with the theme of this review article, one main goal of the AURORA study is to discover circulating risk biomarkers that identify vulnerable individuals in the early aftermath of trauma exposure. Therefore, blood samples are collected from all individuals immediately following enrollment (n=5,000; left). Additional blood samples are collected from a subset of participants two weeks (n=800; middle) and six months (n=3,000; right) following trauma exposure. These longitudinal samples are collected at either Deep Phenotyping sessions when additional multilayered data are collected (e.g. functional and structural MRI, pain physiology, startle response) or via Mobile phlebotomy/participant return to the Emergency Department. Longitudinal blood samples can be used to assess trajectories of risk biomarkers and/or to identify diagnostic biomarkers using nested case-control samples. D = DNA PAXgene tube, R = RNA PAXgene tube, P = EDTA tube for plasma, ED = Emergency Department. All sample sizes represent planned cohort sizes based on enrollment rates and funding as of the date of publication of this review. All samples and processed data derived from the AURORA cohort will be available to the full research community in Fall 2022.
### Table 1.
Summary of results from previous longitudinal studies examining circulating blood-based susceptibility/risk biomarkers of adverse posttraumatic neuropsychiatric sequelae (APNS)

| Reference                  | Type of APNS | Sample Size/Description | Clinical measures | Biological markers                          | Main Finding                                                                 |
|----------------------------|--------------|--------------------------|-------------------|--------------------------------------------|------------------------------------------------------------------------------|
| Vaiva et al. 2004^41       | PTSD         | 108 motor vehicle collision survivors presenting to ED | DSM IV criteria for PTSD given 6 weeks after trauma | GABA levels in plasma γ | Lower plasma GABA levels are associated with higher risk for PTSD development. |
| Segrnan et al. 2005^87      | PTSD         | 33 male and female trauma survivors presenting to the ED | DSM IV PTSD criteria given 1 and 4 months after trauma | Genome-wide mRNA expression in PBMC | Peripheral gene expression signatures following trauma identify evolving PTSD and are informative of its key clinical features and outcome. |
| Pervanidou et al. 2007^99   | PTSD         | 56 children and adolescents enrolled following motor vehicle collision; matched to 40 controls | PTSD part of the K-SADS-PL given 1 and 6 months after trauma | serum and salivary cortisol, serum IL-6 and plasma catecholamines | Increased peritraumatic circulating morning IL-6 levels and increased evening salivary cortisol levels predicted PTSD 6 months later |
| Cohen et al. 2011^78        | PTSD         | 48 patients hospitalized after orthopedic injuries and 13 gender-matched healthy volunteers | PDDS given 1 month after trauma exposure | Serum levels of multiple cytokines, including IL-6, IL-8, TGF-β, IL-4, and IL-10 | Higher levels of IL-8 and lower levels of TGF-β were associated with subsequent higher PTSD symptoms. |
| Inslicht et al. 2011^79     | PTSD         | 296 police officers enrolled during academy training | DSM IV criteria for PTSD given 12, 24, 36 months after training | Cortisol awakening response (change in cortisol from first awakening to 30 minutes later) | Pre-trauma cortisol awakening responses did not predict PTSD symptoms. |
| Van Zuiden et al. 2011^68   | PTSD         | 68 male Dutch military personnel deployed to Afghanistan | SRIP given 6 months after deployment | GR Number and mRNA expression of GR targets in PBMC | Predeployment higher GR number, but not mRNA expression of GR targets, predicts risk for the development of PTSD symptoms after military deployment. |
| Van Zuiden et al. 2012^59   | PTSD         | 448 male Dutch military personnel deployed to combat | SRIP given 6 months after deployment | GR Number and mRNA expression of GR targets in PBMC | Predeployment higher GR number, lower FKBP5 mRNA, and higher GILZ, but not SGK1 mRNA or cortisol levels, predict PTSD after military deployment. |
| Glatt et al. 2013^30        | PTSD         | 48 male US marines deployed to Iraq or Afghanistan | PCL score | Genome-wide mRNA expression in leukocytes | Dysregulated gene expression profiles enriched for immunity-related genes precede the development of PTSD. |
| Eraly et al. 2014^40        | PTSD         | 2208 male infantry battalions imminently deploying to a war zone | CAPS given 3 and 6 months after deployment | Plasma CRP levels | Plasma CRP was prospectively associated with PTSD symptoms. |
| Van Zuiden et al. 2015^71   | PTSD         | 721 male and female Dutch soldiers deployed to Afghanistan | CAPS and SCL-90 given 1 and 6 months after deployment | Glucocorticoid sensitivity in whole blood | Pre-deployment glucocorticoid sensitivity predicts PTSD and depression symptoms 6 months after deployment. |
| Breen et al. 2015^80        | PTSD         | 94 male U.S. marines (dataset I) and 48 male U.S. marines (dataset II) deployed for combat in Iraq or Afghanistan; | CAPS given 1 month pre and 3 months post deployment | Leukocyte mRNA expression using co-regulated gene networks | Over-expression of genes enriched for functions of innate-immune response and interferon signalling (Type-I and Type-II) as resiliency signatures. |
| Gandubert et al. 2016^90    | PTSD         | 123 male and female individuals enrolled in | French version of the Watson’s PTSD cortisol, norepinephrine, | | higher levels of 12 h-overnight urinary norepinephrine | |

*Mol Psychiatry. Author manuscript; available in PMC 2020 September 11.*
| Reference       | Type of APNS | Sample Size/Description                                                                 | Clinical measures                                                                 | Biological markers                                                                 | Main Finding                                                                                                                                 |
|-----------------|--------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Reijnen et al. 2017<sup>72</sup> | PTSD         | 907 male Dutch military personnel deployed to Afghanistan                               | SRIP given 1 and 6 months and 1, 2, and 5 years after deployment                  | Plasma oxytocin and vasopressin levels                                              | Pre-deployment oxytocin and vasopressin levels did not significantly predict PTSD symptoms up to 5 years after deployment.                |
| Reijnen et al. 2018<sup>77</sup> | PTSD         | 3319 Dutch male military personnel deployed to Iraq or Afghanistan                     | SRIP and CAPS up to 6 months after deployment                                     | Plasma neuropeptide Y                                                             | Predeployment plasma NPY was not associated with PTSD symptoms over time.                                                                   |
| Michopoulos et al. 2019<sup>44</sup> | PTSD         | 274 participants presenting to the ED after trauma exposure                             | PSS delivered 1, 3, 6, and 12 months after trauma                                 | Plasma levels of twenty-seven cytokines, chemokines, and growth factors            | Lower TNFα and IFNγ levels at the time of ER presentation were associated with chronic PTSD. None of the other measured markers were associated with PTSD outcomes. |
| Vaiva et al. 2006<sup>70</sup>   | PTSD, Depression | 78 motor vehicle collision survivors presenting to ED                                   | DSM IV criteria for PTSD and major depression 6 weeks and 1 year after trauma  | GABA levels in plasma                                                             | A plasma GABA level below 0.20 mmol/ml is associated with chronic PTSD and depression.                                                   |
| Van Zuiden et al. 2012<sup>74</sup> | PTSD, Depression | 526 male Dutch military personnel deployed to Afghanistan                             | SRIP and SCL-90 given 6 months after deployment                                  | Glucocorticoid sensitivity in whole blood; GR number and mRNA expression of gene targets in PBMC | Lower glucocorticoid sensitivity predicts lower PTSD and higher depression symptoms 6 months after military deployment. GR pathway components predict 6-month PTSD symptoms only. |
| Walsh et al. 2013<sup>73</sup>   | PTSD, Depression | 235 female sexual assault survivors presenting to the ED                                 | PSS-SR and BDI given 6, 12, and 24 weeks after trauma                           | Serum cortisol                                                                    | Higher ER cortisol levels predict higher PTSD and depression symptoms 6 weeks after trauma but lower symptoms over time.                  |
| Yu et al. 2018<sup>75</sup>     | PTSD, Pain    | 65 African American female motor vehicle collision survivors                           | Impact of Event Scale and modified regional pain scale given 6 months after trauma | mRNA expression of X chromosome gene transcripts in whole blood                   | Genes known to escape X chromosome inactivation predict co-morbid chronic musculoskeletal pain and posttraumatic stress symptom development in women following trauma exposure. |
| Linnstaedt et al. 2019<sup>84</sup> | PTSD, Pain    | 179 African American male and female motor vehicle collision survivors presenting to the ED and 74 female sexual assault survivors presenting to SANE sites | Impact of Event Scale and modified regional pain scale given 6 months after trauma | MicroRNA-19b expression in whole blood                                             | microRNA-19b predicts risk for PTSD and chronic pain in a sex-dependent manner following trauma. Relationship between microRNA-19b and PTSD in women was replicated across two independent cohorts. |
| Linnstaedt et al. 2019<sup>82</sup> | Pain         | 53 African American male and female motor vehicle collision survivors presenting to the ED | Numeric rating (0 –10) pain scale given 6 weeks after trauma                     | MicroRNA expression in whole blood                                                 | MicroRNAs circulating in the early aftermath of motor vehicle collision predict persistent pain development in sex-specific and suggest a role for microRNA in pain differences. |
| Mauck et al. 2019<sup>85</sup>   | Pain         | 133 African American male and female motor vehicle collision                           | Numeric rating (0 –10) pain scale given 6 weeks, 6                               | Plasma Vitamin D levels                                                            | Low Vitamin D levels in the peritraumatic period predict higher pain levels over the |
| Reference       | Type of APNS | Sample Size/Description | Clinical measures | Biological markers | Main Finding                                                                                                                                 |
|-----------------|--------------|-------------------------|-------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Rushton et al.  | Pain,        | 500 male and female     | Chronic Pain Grade| CRP and cfDNA     | Protocol for developing a screening tool to predict chronic pain and disability after musculoskeletal trauma.                                |
| 2018            | Disability   | patients with acute     | Scale given 6     | in plasma         |                                                                                                                                               |
|                 |              | musculoskeletal trauma  | months after trauma|                  |                                                                                                                                               |

**Abbreviations:** BDI, Beck Depression Inventory; cfDNA, cell-free DNA; CRP, C-reactive protein; DSM, diagnostic and statistical manual for mental disorders; ED, emergency department; SANE, sexual assault nurse examiner; GR, glucocorticoid receptor; PBMC, peripheral blood mononuclear cells; PCL, PTSD Checklist based on the Clinician-Administered PTSD Scale (CAPS); PDSS, Posttraumatic Disorder Symptom Scale (PDSS); K-SADS-PL, Kiddie Schedule for Affective Disorders and Schizophrenia – Present and Lifetime version; PSS-SR, PTSD Symptom Scale—Self-Report; PTSD, posttraumatic stress disorder; SCL-90, 16-item Symptom Checklist–90 depression subscale; SRIP, Self-rating inventory for PTSD; VAS, 10cm visual analogue scale (0–10) for assessing pain.